Literature DB >> 25332550

A case of pediatric acute lymphoblastic leukemia with invasive candidiasis: short review.

S P Verma1, B Dubashi1, P Narayanan1, D Basu1, T K Dutta1, K M Dhanraj1.   

Abstract

Mortality rate associated with invasive fungal infections is very high. Early suspicion for fungal infections is important during intensive chemotherapy for acute leukemia. Empirical treatment with antifungals amphotericin B or caspofungin should be started if patient is not responding to broad spectrum antibiotics and if expected duration of neutropenia is prolonged. We are reporting a 3 years old girl child with diagnosis of pre-B acute lymphoblastic leukemia who developed invasive candidiasis with typical clinical and radiological findings during induction chemotherapy. Candida non-albicans was isolated and she was treated with amphotericin B followed by caspofungin. Patient deteriorated after initial response and succumbed to death. Species identification and sensitivity pattern of fungus can help in selecting appropriate antifungal drug.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Candida non-albicans; Invasive candidiasis

Year:  2013        PMID: 25332550      PMCID: PMC4192173          DOI: 10.1007/s12288-013-0274-z

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  17 in total

Review 1.  The changing face of fungal infections in health care settings.

Authors:  Scott K Fridkin
Journal:  Clin Infect Dis       Date:  2005-10-13       Impact factor: 9.079

2.  Fungal infections complicating acute leukemia.

Authors:  G P Bodey
Journal:  J Chronic Dis       Date:  1966-06

3.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 4.  Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.

Authors:  Christopher C Blyth; Katherine Hale; Pamela Palasanthiran; Tracey O'Brien; Michael H Bennett
Journal:  Cochrane Database Syst Rev       Date:  2010-02-17

5.  Safety experience with caspofungin in pediatric patients.

Authors:  Theoklis Zaoutis; Thomas Lehrnbecher; Andreas H Groll; William J Steinbach; Hasan S Jafri; Johan Maertens; Angela L Ngai; Joseph W Chow; Arlene F Taylor; Kim M Strohmaier; Michael Bourque; Susan K Bradshaw; Maria Petrecz; Nicholas A Kartsonis
Journal:  Pediatr Infect Dis J       Date:  2009-12       Impact factor: 2.129

6.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

Review 7.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

8.  Controlled comparison of the BACTEC high-blood-volume fungal medium, BACTEC Plus 26 aerobic blood culture bottle, and 10-milliliter isolator blood culture system for detection of fungemia and bacteremia.

Authors:  M L Wilson; T E Davis; S Mirrett; J Reynolds; D Fuller; S D Allen; K K Flint; F Koontz; L B Reller
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

9.  Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital.

Authors:  Jorge Garbino; Lenka Kolarova; Peter Rohner; Daniel Lew; Peter Pichna; Didier Pittet
Journal:  Medicine (Baltimore)       Date:  2002-11       Impact factor: 1.889

10.  Epidemiological trends in nosocomial candidemia in intensive care.

Authors:  Matteo Bassetti; Elda Righi; Alessandro Costa; Roberta Fasce; Maria Pia Molinari; Raffaella Rosso; Franco Bobbio Pallavicini; Claudio Viscoli
Journal:  BMC Infect Dis       Date:  2006-02-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.